Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

Presentation THT 2026

Transcriptomic Profiling Reveals Antifibrotic effect of Cannabidiol through Epithelial/Endothelial-to-Mesenchymal Transition inhibition in a Murine Non-Ischemic Heart Failure Model

Presenter: Arvind Bhimaraj

March 03, 2026

Presentation THT 2026

Cardiac Reprogramming Cocktail Delivered in a Single Adeno-Associated Virus to Improve Function in a Porcine Model of Ischemic Heart Failure

Presenter: Kathy Ivey

March 02, 2026

Presentation THT 2026

Autologous Cell Therapy May Curb Pathological Ventricular Remodeling in Chronic Ischemic HFrEF Patients Selected for Favorable Cell Characteristics - Late Breaking Echocardiography Results from the CardiAMP HF trial

Presenter: Amish Raval

March 02, 2026

Presentation THT 2025

Myeloperoxidase Inhibition in Patients With Ischemic or Non-Ischemic Cardiomyopathy and Heart Failure With Reduced Ejection Fraction (MYSTERY-HF)

Presenter: Simon Braumann

February 12, 2025

Presentation THT 2024

CMR in Ischemic Cardiomyopathy

Presenter: Jonathan Weinsaft

March 05, 2024

Presentation THT 2024

Alternative Advanced Therapy: Case of Cardiac Contractility Modulation in Stage D Ischemic Cardiomyopathy

Presenter: Daniel Asemota

March 05, 2024

Presentation THT 2023

Left ventricular reconstruction compared to optimal medical therapy in patients with ischemic cardiomyopathy

Presenter: Oleg Polonetsky

March 21, 2023

Presentation THT 2023

The Role of Guideline Directed Medical Therapy in Functional Improvement after Hybrid Left Ventricular Reconstruction for the Treatment of Ischemic Heart Failure

Presenter: Romy Hegeman

March 21, 2023

Advertisement

Transcriptomic Profiling Reveals Antifibrotic effect of Cannabidiol through Epithelial/Endothelial-to-Mesenchymal Transition inhibition in a Murine Non-Ischemic Heart Failure Model

Cardiac Reprogramming Cocktail Delivered in a Single Adeno-Associated Virus to Improve Function in a Porcine Model of Ischemic Heart Failure

Autologous Cell Therapy May Curb Pathological Ventricular Remodeling in Chronic Ischemic HFrEF Patients Selected for Favorable Cell Characteristics - Late Breaking Echocardiography Results from the CardiAMP HF trial

Myeloperoxidase Inhibition in Patients With Ischemic or Non-Ischemic Cardiomyopathy and Heart Failure With Reduced Ejection Fraction (MYSTERY-HF)

CMR in Ischemic Cardiomyopathy

Alternative Advanced Therapy: Case of Cardiac Contractility Modulation in Stage D Ischemic Cardiomyopathy

Left ventricular reconstruction compared to optimal medical therapy in patients with ischemic cardiomyopathy

The Role of Guideline Directed Medical Therapy in Functional Improvement after Hybrid Left Ventricular Reconstruction for the Treatment of Ischemic Heart Failure

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content